Keywords: MEI Pharma, S*BIO, Pracinostat, Hematological disorders, Solid tumors

MEI Pharma to acquire S*BIO's pracinostat

Article | 08 August 2012

Print This

US cancer drug developer MEI Pharma (Nasdaq: MEIP) has entered into a definitive asset purchase agreement with Singapore’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in